HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Takes “Property”-Based Approach To Nanotech, Raises Roof To 1 Micron

This article was originally published in The Rose Sheet

Executive Summary

In its newly released guidance to industry, FDA indicates that “agglomerates and aggregates” of materials that exceed the oft-cited ceiling of 100 nanometers may still warrant consideration as nanotechnology based on their “properties,” a position that could impact the cosmetics sector.

You may also be interested in...

In Nanotech Metrics, Safety Should Trump Size, Experts Say

Evaluations of novel products based on nanotechnology should focus on safety and efficacy more than particle size, presenters at the FDLI annual conference say. The Project on Emerging Nanotechnologies is updating its product inventory to include more nanomaterial safety data.

Congress Instructs FDA On Nanotech Work, But Mute On Funding

Newly passed user-fee legislation includes a provision directing FDA to intensify its research and policy development regarding nanotechnology and its use in consumer products. How such efforts are to be funded remains a question.

Nanotech Is “More Than Just Tiny,” Requires FDA Regulation – Lawsuit

A suit filed in U.S. District Court Dec. 21 by coalition of advocacy groups says FDA's failure to respond "meaningfully" to 2006 citizen petition on nanotechnology violates federal law. Lawsuit asks court to order FDA to respond to their peititon without further delay.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts